WO2025110436A1 - Antimicrobial composition applicable to powder formulation - Google Patents

Abstract

The present invention relates to an antimicrobial composition applicable to a powder formulation, the antimicrobial composition containing a combination of caprylyl glycol, ethylhexylglycerin, and p-anisic acid, or a combination of 1,3-propanediol, methylpropanediol, and p-anisic acid. Due to containing a combination of specific components, when the antibacterial composition is applied to a powder formulation, the antibacterial composition exhibits appropriate antiseptic properties even at a low content, and the powder formulation has excellent stability because mold mycelium or moisture condensation is prevented from occurring even in a high humidity environment.

Description

Antibacterial composition applicable to powder formulations

It relates to an antibacterial composition applicable to powder formulations.

Powder formulations are a type of cosmetic that is less likely to harbor microorganisms because they do not contain water. However, if the tableted product is distributed or stored in a high temperature and humidity environment, it can cause microbial contamination such as mold because it provides a surface on which microorganisms can grow.

However, due to the nature of cosmetic preservatives that effectively exhibit antibacterial activity in water, antibacterial raw materials applicable to powders are very limited, and very high contents must be used when used alone.

Therefore, it is necessary to discover preservative raw materials that can be applied to powder formulations that can effectively inhibit the growth of microorganisms such as bacteria, yeast, and mold in various environments.

One aspect is to provide an antimicrobial composition applicable to a powder formulation, comprising caprylyl glycol, ethylhexylglycerin, and p-anisic acid.

Another aspect is to provide an antimicrobial composition applicable to a powder formulation, comprising 1,3-propanediol, methylpropanediol, and p-anisic acid.

Another aspect is to provide a cosmetic composition comprising an antimicrobial composition applicable to the above powder formulation.

Another aspect is to provide a composition for external use in the skin comprising an antibacterial composition applicable to the powder formulation.

Another aspect is to provide a pharmaceutical composition comprising an antimicrobial composition applicable to the above powder formulation.

Another aspect provides the use of a combination of caprylyl glycol, ethylhexylglycerin, and p-anisic acid for preparing an antimicrobial composition applicable to a powder formulation.

Another aspect provides the use of a combination of 1,3-propanediol, methylpropanediol, and p-anisic acid for preparing an antimicrobial composition applicable to a powder formulation.

One aspect provides an antimicrobial composition applicable to a powder formulation, comprising caprylyl glycol, ethylhexylglycerin, and p-anisic acid.

The above antibacterial composition comprises a combination of caprylyl glycol, ethylhexylglycerin, and p-anisic acid.

The weight ratio of caprylyl glycol, ethylhexylglycerin, and p-anisic acid may be 1 to 32:1 to 16:1 to 32, 1 to 2:1 to 8:1 to 32, 1 to 2:2 to 4:1, 1 to 8:1:1 to 32, 1 to 32:1:1 to 8, 1 to 8:1 to 16:1, 1 to 7:1 to 5:1 to 3, 4 to 6:4 to 6:2 to 4, 4 to 6:4 to 6:3, or 5:5:3. The weight ratio of caprylyl glycol, ethylhexylglycerin, and p-anisic acid may be any range or any value selected from the above ranges. If the above weight ratio is out of the above range, the powder formulation may exhibit unsuitable preservative properties, or mold mycelia or moisture may form in the powder formulation, which may reduce the stability of the formulation.

When the weight ratio of caprylyl glycol, ethylhexylglycerin, and p-anisic acid is 1 to 2:1 to 8:1 to 32, an antibacterial synergistic effect against Escherichia coli can be exhibited. When the weight ratio of caprylyl glycol, ethylhexylglycerin, and p-anisic acid is 1 to 2:2 to 4:1, an antibacterial synergistic effect against P. aeruginosa can be exhibited. When the weight ratio of caprylyl glycol, ethylhexylglycerin, and p-anisic acid is 1 to 8:1:1 to 32, an antibacterial synergistic effect against Staphylococcus aureus can be exhibited. When the weight ratio of caprylyl glycol, ethylhexylglycerin, and p-anisic acid is 1 to 32:1:1 to 8, an antibacterial synergistic effect against yeast ( C. albicans ) can be exhibited. When the weight ratio of caprylyl glycol, ethylhexylglycerin, and p-anisic acid is 1 to 8:1 to 16:1, an antibacterial synergistic effect against mold ( A. brasiliensis ) can be exhibited.

In one specific embodiment, the caprylyl glycol is present in an amount of 0.004 to 5 wt%, 0.004 to 3 wt%, 0.004 to 1 wt%, 0.004 to 0.7 wt%, 0.004 to 0.6 wt%, 0.04 to 5 wt%, 0.04 to 3 wt%, 0.04 to 1 wt%, 0.04 to 0.7 wt%, 0.04 to 0.6 wt%, 0.1 to 5 wt%, 0.1 to 3 wt%, 0.1 to 1 wt%, 0.1 to 0.7 wt%, 0.1 to 0.6 wt%, 0.1 to 0.5 wt%, 0.1 to 0.4 wt%, 0.2 to 0.7 wt%, 0.2 to 0.6 %, 0.2 to 0.5 wt %, 0.2 to 0.4 wt %, 0.3 to 0.7 wt %, 0.3 to 0.6 wt %, 0.3 to 0.5 wt %, 0.3 to 0.4 wt %, 0.4 to 0.7 wt %, or 0.4 to 0.6 wt %. If the content of caprylyl glycol is out of the above range, problems such as microbial contamination due to weakening of antimicrobial synergy between preservative raw materials or skin irritation due to excessive preservative content may occur.

In one specific embodiment, the ethylhexylglycerin is present in an amount of 0.004 to 5 wt%, 0.004 to 3 wt%, 0.004 to 1 wt%, 0.004 to 0.7 wt%, 0.004 to 0.6 wt%, 0.04 to 5 wt%, 0.04 to 3 wt%, 0.04 to 1 wt%, 0.04 to 0.7 wt%, 0.04 to 0.6 wt%, 0.1 to 5 wt%, 0.1 to 3 wt%, 0.1 to 1 wt%, 0.1 to 0.7 wt%, 0.1 to 0.6 wt%, 0.1 to 0.5 wt%, 0.1 to 0.4 wt%, 0.2 to 0.7 wt%, 0.2 to 0.6 %, 0.2 to 0.5 wt %, 0.2 to 0.4 wt %, 0.3 to 0.7 wt %, 0.3 to 0.6 wt %, 0.3 to 0.5 wt %, 0.3 to 0.4 wt %, 0.4 to 0.7 wt %, or 0.4 to 0.6 wt %. If the content of ethylhexylglycerin is out of the above range, problems such as microbial contamination due to weakening of antimicrobial synergy between preservative ingredients or skin irritation due to excessive preservative content may occur.

In one specific example, the p-anisic acid may be included in an amount of 0.02 to 0.5 wt%, 0.02 to 0.4 wt%, 0.02 to 0.3 wt%, 0.1 to 0.5 wt%, 0.1 to 0.4 wt%, 0.1 to 0.3 wt%, 0.2 to 0.5 wt%, 0.2 to 0.4 wt%, or 0.2 to 0.3 wt% based on the total weight of the composition. If the content of p-anisic acid is out of the above range, problems such as microbial contamination due to weakened antibacterial synergy between preservative raw materials, skin irritation due to excessive preservative content, or weakened formulation stability due to precipitation of raw materials may occur.

When the above antibacterial composition is applied to a composition in a powder formulation (e.g., a cosmetic composition), the content of each of caprylyl glycol, ethylhexylglycerin, and p-anisic acid may be the content relative to the total weight of the composition in the powder formulation.

Another aspect provides an antimicrobial composition applicable to a powder formulation, comprising 1,3-propanediol, methylpropanediol, and p-Anisic Acid.

The above antibacterial composition comprises a combination of 1,3-propanediol, methylpropanediol, and p-anisic acid.

The weight ratio of the above 1,3-propanediol, methylpropanediol, and p-anisic acid may be 1 to 512:1 to 512:1, 2 to 128:1 to 32:1, 8 to 32:32 to 64:1, 1 to 128:1 to 128:1, 4 to 512:4 to 512:1, 8 to 256:4 to 256:1, 5 to 10:5 to 10:1 to 3, 4 to 6:9 to 11:2 to 4, 4 to 6:9 to 11:3, or 5:10:3. The weight ratio of the above 1,3-propanediol, methylpropanediol, and p-anisic acid may be any range or value selected from the above range. If the weight ratio is out of the above range, the powder formulation may exhibit unsuitable preservative properties, or mold mycelia or moisture may occur in the powder formulation, thereby reducing the stability of the formulation.

When the weight ratio of the above 1,3-propanediol, methylpropanediol, and p-anisic acid is 2 to 128:1 to 32:1, it can exhibit an antibacterial synergistic effect against Escherichia coli . When the weight ratio of the above 1,3-propanediol, methylpropanediol, and p-anisic acid is 8 to 32:32 to 64:1, it can exhibit an antibacterial synergistic effect against P. aeruginosa . When the weight ratio of the above 1,3-propanediol, methylpropanediol, and p-anisic acid is 1 to 128:1 to 128:1, it can exhibit an antibacterial synergistic effect against Staphylococcus aureus . When the weight ratio of the above 1,3-propanediol, methylpropanediol, and p-anisic acid is 4 to 512:4 to 512:1, an antibacterial synergistic effect against yeast ( C. albicans ) can be exhibited. When the weight ratio of the above 1,3-propanediol, methylpropanediol, and p-anisic acid is 8 to 256:4 to 256:1, an antibacterial synergistic effect against mold ( A. brasiliensis ) can be exhibited.

In one specific embodiment, the 1,3-propanediol is present in an amount of 0.25 to 32 wt%, 0.25 to 16 wt%, 0.25 to 8 wt%, 0.25 to 4 wt%, 0.25 to 2 wt%, 0.25 to 1 wt%, 0.25 to 0.8 wt%, 0.25 to 0.5 wt%, 0.3 to 32 wt%, 0.3 to 16 wt%, 0.3 to 8 wt%, 0.3 to 4 wt%, 0.3 to 2 wt%, 0.3 to 1 wt%, 0.3 to 0.8 wt%, 0.3 to 0.5 wt%, 0.35 to 32 wt%, 0.35 to 16 wt%, 0.35 to 8 wt%, It can be included at 0.35 to 4 wt%, 0.35 to 2 wt%, 0.35 to 1 wt%, 0.35 to 0.8 wt%, or 0.35 to 0.5 wt%. If the content of 1,3-propanediol is out of the above range, problems such as microbial contamination due to weakening of antibacterial synergy between preservative ingredients or skin irritation due to excessive preservative content may occur.

In one specific embodiment, the methylpropanediol is present in an amount of 0.25 to 32 wt%, 0.25 to 16 wt%, 0.25 to 8 wt%, 0.25 to 4 wt%, 0.25 to 2 wt%, 0.25 to 1.5 wt%, 0.25 to 1 wt%, 0.5 to 32 wt%, 0.5 to 16 wt%, 0.5 to 8 wt%, 0.5 to 4 wt%, 0.5 to 2 wt%, 0.5 to 1.5 wt%, 0.5 to 1 wt%, 0.7 to 32 wt%, 0.7 to 16 wt%, 0.7 to 8 wt%, 0.7 to 4 wt%, 0.7 to 2 wt%, 0.7 to 1.5 wt%, or It can be included at 0.7 to 1 wt%. If the content of methylpropanediol is outside the above range, problems such as microbial contamination due to weakening of antibacterial synergy between preservative ingredients or skin irritation due to excessive preservative content may occur.

In one specific example, the p-anisic acid may be included in an amount of 0.02 to 0.5 wt%, 0.02 to 0.4 wt%, 0.02 to 0.3 wt%, 0.1 to 0.5 wt%, 0.1 to 0.4 wt%, 0.1 to 0.3 wt%, 0.2 to 0.5 wt%, 0.2 to 0.4 wt%, or 0.2 to 0.3 wt% based on the total weight of the composition. If the content of p-anisic acid is out of the above range, problems such as microbial contamination due to weakened antibacterial synergy between preservative raw materials, skin irritation due to excessive preservative content, or weakened formulation stability due to precipitation of raw materials may occur.

When the above antibacterial composition is applied to a composition in a powder formulation (e.g., a cosmetic composition), the content of each of the 1,3-propanediol, methylpropanediol, and p-anisic acid may be the content relative to the total weight of the composition in the powder formulation.

The antimicrobial composition according to the above aspects is applicable to a powder formulation. The term 'applicable to powder formulation' may mean that it can be used as a preservative in a final product of a powder formulation. Unlike general cosmetic preservatives that are used for the purpose of applying to cosmetics of a formulation containing water, the antimicrobial composition according to the above aspects is applicable to a powder formulation that does not contain water. The antimicrobial composition according to the above aspects exhibits a preservative effect suitable for a powder formulation even at a low content by including a combination of three specific components. In addition, a powder formulation product to which the antimicrobial composition according to the above aspects is applied does not develop mold mycelia or moisture condensation even when distributed or stored in a high temperature and humidity environment.

As used herein, the term “antimicrobial composition” means a composition that kills or inhibits the growth of microorganisms (e.g., bacteria, yeast, mold, etc.), and may be used interchangeably with the term “preservative composition” or “septic composition.”

The antimicrobial composition according to the above aspects can exhibit antimicrobial activity against one or more selected from bacteria, yeast, and mold.

The above bacteria may include, but are not limited to, one or more species selected from Escherichia coli , Pseudomonas aeruginosa , and Staphylococcus aureus .

The yeast may include, but is not limited to, Candida albicans.

The above mold may include, but is not limited to, Aspergillus brasiliensis .

A powder formulation product to which an antimicrobial composition according to the above aspects is applied does not cause mold mycelia or moisture condensation even when distributed or stored in a high-temperature and humid environment. The high-temperature and humid environment may mean, for example, a condition of a relative humidity of 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, or 90% or more and a temperature of 25°C or more, 30°C or more, 32°C or more, 35°C or more, or between 25°C and 40°C. In one embodiment, when a cosmetic composition in a powder formulation to which an antimicrobial composition according to the above aspects is applied was incubated at a temperature of 25°C (room temperature) or 32°C (high temperature) for 28 days at a relative humidity of 95%, it was confirmed that no mold mycelia were generated and no moisture condensation occurred.

Another aspect provides a cosmetic composition comprising an antimicrobial composition applicable to a powder formulation according to the above aspect.

The above cosmetic composition is not particularly limited to a specific formulation, and the formulation may be appropriately selected depending on the purpose. In one specific example, the cosmetic composition may be in a powder formulation.

The above cosmetic composition may additionally include ingredients commonly used in cosmetic compositions, functional additives, etc., and may include conventional auxiliary agents such as antioxidants, stabilizers, vitamins, pigments, fragrances, etc., and carriers.

Another aspect provides a composition for external use in the skin comprising an antibacterial composition applicable to a powder formulation according to the above aspect.

In one specific example, the skin external preparation composition may be in a powder formulation.

The above skin external preparation may be appropriately mixed with ingredients commonly used in skin external preparations such as cosmetics, medicines, and quasi-drugs, such as powder ingredients, ultraviolet absorbers, whitening agents, antioxidants, fragrances, colorants, various skin nutrients, metal ion sequestrants, sugars, or combinations thereof, as needed.

Another aspect provides a pharmaceutical composition comprising an antimicrobial composition applicable to a powder formulation according to the above aspect.

The above antibacterial composition can be included as an active ingredient of a pharmaceutical composition having antibacterial activity, or used as an auxiliary agent of an active ingredient having a pharmaceutical use.

In one specific embodiment, the pharmaceutical composition may be in a powder formulation.

Another aspect provides the use of a combination of caprylyl glycol, ethylhexylglycerin, and p-anisic acid for preparing an antimicrobial composition applicable to a powder formulation.

Another aspect provides the use of a combination of 1,3-propanediol, methylpropanediol, and p-anisic acid for preparing an antimicrobial composition applicable to a powder formulation.

Duplicate contents are omitted in consideration of the complexity of this specification, and terms not otherwise defined herein have the meaning commonly used in the technical field to which the present invention belongs.

An antibacterial composition according to one aspect comprises a combination of caprylyl glycol, ethylhexylglycerin, and p-anisic acid; or a combination of 1,3-propanediol, methylpropanediol, and p-anisic acid, thereby exhibiting suitable preservative properties even at a low content when applied to a powder formulation, and has excellent stability because no mold mycelia or moisture formation occurs in the powder formulation in a high humidity environment. Therefore, the antibacterial composition can be used as a preservative in powder formulation cosmetics, external skin preparations, etc.

Figure 1 is a photograph showing the result of incubating a powder formulation (Sample No. 3-2) containing a combination of caprylyl glycol, ethylhexylglycerin, and p-anisic acid as antibacterial raw materials in a high humidity environment.

Figure 2 is a photograph showing the result of incubating a powder formulation (Sample No. 4-3) containing a combination of 1,3-propanediol and methylpropanediol as antibacterial raw materials in a high humidity environment.

Figure 3 is a photograph showing the result of incubating a powder formulation (Sample No. 4-4) containing a combination of 1,3-propanediol and methylpropanediol as antibacterial raw materials in a high humidity environment.

Figure 4 is a photograph showing the result of incubating a powder formulation (sample No. 4-5) containing a combination of 1,3-propanediol and methylpropanediol as antibacterial raw materials in a high humidity environment.

Figure 5 is a photograph showing the result of incubating a powder formulation (Sample No. 5-2) containing a combination of 1,3-propanediol, methylpropanediol, and p-anisic acid as antibacterial raw materials in a high humidity environment.

The following examples are provided to illustrate in more detail. However, these examples are provided only to illustrate one or more specific examples, and the scope of the present invention is not limited to these examples.

Example 1: Confirmation of antibacterial synergy effect

The three-dimensional antibacterial synergy of the combination of caprylyl glycol, ethylhexylglycerin, and p-anisic acid and the combination of 1,3-propanediol, methylpropanediol, and p-anisic acid was confirmed. The specific antibacterial synergy test method is as follows. The concentration of the raw materials was based on the minimum inhibitory concentration (MIC) of each raw material.

When testing for bacteria, dilute with Tryptic Soy Agar (TSA) and when testing for fungi, dilute with Sabouraud Dextrose Agar (SDA) to the desired concentration. To confirm the minimum inhibitory concentration of the raw material, add 100 ㎕ of the bacterial solution with the adjusted number of bacteria to a 96-well plate. Add 100 ㎕ of the prepared raw material to the first row of the plate containing 100 ㎕ of the bacterial solution, mix the bacterial solution and the raw material well, and add 100 ㎕ to the second row so that the raw material is diluted by 1/2. In this way, after diluting the raw material by 1/2 in stages, discard the 100 ㎕ mixed solution remaining in the last row. After plate culture, check the turbidity of the medium to visually determine whether the bacteria have grown. When looking at the turbidity, the lowest concentration at which no bacteria grew is determined as the minimum inhibitory concentration value for the raw material. The minimum inhibitory concentration (weight%) of the raw material for each strain measured in this test is as shown in Table 1.

For the purpose of confirming the antibacterial synergy effect, raw material A (caprylyl glycol or 1,3-propanediol), raw material B (ethylhexylglycerin or methylpropanediol), and raw material C (p-anisic acid) are prepared to have 8 times the minimum inhibitory concentration. By diluting the prepared raw materials by 1/2 each using tryptic soy medium, raw materials A and B are prepared by diluting raw materials from 8 times the minimum inhibitory concentration to 1/8. Raw material C is prepared by diluting raw materials from 8 times the minimum inhibitory concentration to 1 time.

Dispense 25 ㎕ of Type A raw material from low concentration (1/8 of the minimum inhibitory concentration) to high concentration (8 times the minimum inhibitory concentration) into wells of the X-axis row of a 96-well plate. Dispense 25 ㎕ of Type B raw material from low concentration (1/8 of the minimum inhibitory concentration) to high concentration (8 times the minimum inhibitory concentration) into wells of the Y-axis column. Dispense 25 ㎕ of Type C raw material from low concentration (minimum inhibitory concentration) to high concentration (8 times the minimum inhibitory concentration) into wells of the Z-axis plate of a 96-well plate. Dispense 25 ㎕ of each bacterial solution with the same number of bacteria into all wells containing the raw material and culture.

A 96-well plate containing E. coli, P. aeruginosa, and S. aureus strains and diluted raw materials is cultured in an incubator at 32°C for 24 hours, and a 96-well plate containing C. albicans and A. brasiliensis strains and diluted raw materials is cultured in an incubator at 25°C for 48 hours. The mixing ratio (weight ratio) of the minimum concentration at which bacterial growth is not observed with the naked eye is confirmed.

To confirm the most efficient mixing concentration results, the fractional inhibiting concentration (FIC) and FIC index are calculated by substituting them into the following mathematical formula.

[Mathematical formula 1]

FIC of substance A, B or C = (MIC of raw material A, B or C in the mixture) / (MIC when raw material A, B or C is used alone)

[Mathematical formula 2]

FIC index = FIC of substance A + FIC of substance B + FIC of substance C

If the range where the fungus does not grow is the FIC index ≤ 0.5, it is considered to have a synergistic effect; if 0.5 < FIC index ≤ 1, it is considered to have a partial synergistic effect; if 1 < FIC index ≤ 4, it is considered to have an indifferent effect; and if the FIC index > 4, it is considered to have an antagonistic effect.

In this test, caprylyl glycol was used in an amount of 0.004 to 0.5 wt%, ethylhexylglycerin in an amount of 0.004 to 1 wt%, 1,3-propanediol and methylpropanediol in an amount of 0.25 to 32 wt%, and p-anisic acid in an amount of 0.02 to 0.5 wt%, based on the minimum inhibitory concentration content of each raw material. The results of the antibacterial synergy test of the combination of caprylyl glycol, ethylhexylglycerin, and p-anisic acid and the combination of 1,3-propanediol, methylpropanediol, and p-anisic acid are shown in Table 2 below in the weight ratio showing the synergy between the raw materials.

<Abbreviation>

CG: Caprylyl glycol

EHG: Ethylhexylglycerin

p-AA: p-Anisic acid

1,3-PD: 1,3-Propanediol

MPD: Methylpropanediol

As shown in Table 2 above, the results of the antibacterial synergy test against bacteria showed that the combination of caprylyl glycol, ethylhexylglycerin, and p-anisic acid exhibited antibacterial synergy against Escherichia coli ( E. coli ) at a weight ratio of 1 to 2:1 to 8:1 to 32, antibacterial synergy against Pseudomonas aeruginosa ( P. aeruginosa ) at a weight ratio of 1 to 2:2 to 4:1, and antibacterial synergy against Staphylococcus aureus ( S. aureus ) at a weight ratio of 1 to 8:1:1 to 32. It exhibited antibacterial synergy against yeast ( C. albicans ) at a weight ratio of 1 to 32:1:1 to 8. It exhibited antibacterial synergy against fungi ( A. brasiliensis ) at a weight ratio of 1 to 8:1 to 16:1 to 16. The combination of 1,3-propanediol, methylpropanediol, and p-anisic acid exhibited antibacterial synergy against Escherichia coli ( E. coli ) at a weight ratio of 2 to 128:1 to 32:1, against Pseudomonas aeruginosa at a weight ratio of 8 to 32:32 to 64:1, and against Staphylococcus aureus ( S. aureus ) at a weight ratio of 1 to 128:1 to 128:1. Against yeast, it exhibited antibacterial synergy at a weight ratio of 4 to 512:4 to 512:1. For fungi, antibacterial synergy was shown at weight ratios of 8 to 256:4 to 256:1.

Example 2: Buoyancy test

A preservative test was performed on a powder formulation cosmetic composition containing an antibacterial composition.

First, a cosmetic composition in powder form containing the antibacterial ingredients (in weight %) of Table 3 below was prepared. The cosmetic composition in powder form was prepared by a general method of crushing a powder phase to prepare a powder phase, placing the powder phase into a Henschel mixer, spraying and mixing the oil phase into the Henschel mixer, and then compression molding. Specifically, 70 to 80 wt% of a powder base material and 5 to 10 wt% of a pigment were placed into a mixer and stirred at 1,200 to 1,500 rpm for 1 to 2 minutes to mix. Thereafter, 10 to 20 wt% of an oil binder was mixed by heating to 65 to 85°C, and then sprayed directly onto the mixed powder phase while stirring at 200 to 400 rpm, and then mixed to prepare the composition. The powder base is in a powder phase and includes at least one selected from talc, titanium dioxide, mica, silica, nylon powder, aluminum starch octenylsuccinate, magnesium myristate, magnesium stearate, lauroyl lysine, triethoxycaprylylsilane, and p-anisic acid. The binder is in an oil phase and includes at least one selected from caprylic/capric triglyceride, triethylhexanoin, polyglyceryl-2 triisostearate, hydrogenated castor oil isostearate, caprylyl glycol, ethylhexylglycerin, propanediol, and methylpropanediol. The pigment includes at least one selected from yellow iron oxide, red iron oxide, black iron oxide, selenide sulfide, ferrocyanide, carmine, and manganese violet.

Next, a cosmetic preservative test was performed on the cosmetic composition in the powder formulation manufactured above. Specifically, the test was conducted on Escherichia coli ATCC 8739, Pseudomonas aeruginosa ATCC 9027, and Staphylococcus aureus ATCC 6538 among bacteria; Candida albicans ATCC 10231 among yeasts; and Aspergillus brasiliensis ATCC 16404 among molds. Bacterial (Escherichia coli ATCC 8739, Pseudomonas aeruginosa ATCC 9027, and Staphylococcus aureus ATCC 6538) suspensions were adjusted to have 10 ⁸ CFU/ml of each bacterial count using 0.85% NaCl and mixed, and yeast ( Candida albicans ATCC 10231) and mold ( Aspergillus brasiliensis , ATCC 16404) suspensions were adjusted to have 10 ⁷ CFU/ml of each bacterial count. 1% of bacterial, yeast, and mold suspensions were added to 20 g of the prepared powder formulation and mixed, and then cultured at 25℃ for 4 weeks. The number of bacteria remaining at the 1st, 2nd, and 4th weeks was measured and converted to a log value to confirm the bacterial reduction rate.

The results of the preservative test are shown in Table 3 below.

<Abbreviation>

CG: Caprylyl glycol

EHG: Ethylhexylglycerin

p-AA: p-Anisic acid

1,3-PD: 1,3-Propanediol

MPD: Methylpropanediol

As shown in Table 3 above, p-anisic acid alone (Samples No. 1-1 to 1-3) or a combination of caprylyl glycol and ethylhexylglycerin (Samples No. 2-1 to 2-3) exhibited inadequate preservative properties in powder formulations. A combination of 1,3-propanediol and methylpropanediol (Samples No. 4-1 and 4-2) exhibited adequate preservative properties in powder formulations; however, as can be seen in Example 3 below, mold mycelia grew in the powder formulation or moisture condensation occurred in a high humidity environment, resulting in poor stability.

In contrast, the combination of caprylyl glycol, ethylhexylglycerin, and p-anisic acid (Sample No. 3-1) or the combination of 1,3-propanediol, methylpropanediol, and p-anisic acid (Sample No. 5-1) exhibited suitable preservative properties in powder formulations even at low contents.

Example 3: Mold test and stability evaluation

A fungal test and stability evaluation were performed on a powder formulation cosmetic composition containing an antibacterial composition.

First, a cosmetic composition in powder form containing the antibacterial ingredients (weight %) of Table 4 below was prepared. The method for preparing the cosmetic composition in powder form was the same as in Example 2.

Next, a mold test and stability evaluation were performed on the cosmetic composition in the powder formulation manufactured above. Specifically, 3 μL of the mold fungus solution adjusted to 10 ⁶ CFU/mL was inoculated into at least one area of the cosmetic composition in the compression-molded powder formulation. After incubation for 28 days under the incubation conditions shown in Table 3 below, the occurrence of mold mycelia and moisture formation was confirmed.

The occurrence of fungal mycelia was visually confirmed, and the results were indicated as follows according to the degree of occurrence: -: No mycelia at the inoculation site, +: Mycelia not visible, but spores spread around the inoculation site, ++: A small amount of mycelia is visible around the inoculation site and spores spread, +++: A large amount of mycelia is confirmed around the inoculation site.

The moisture condensation phenomenon was confirmed with the naked eye, and if the moisture condensation phenomenon occurred, it was judged as failing the stability item.

As shown in Table 4 and FIGS. 1 to 5 above, the combination of 1,3-propanediol and methylpropanediol (Samples No. 4-3 to 4-5) exhibited suitable preservative properties in a powder formulation, but had low safety and low stability due to occurrence of mold mycelia or moisture condensation in a high-humidity environment. On the other hand, the combination of caprylyl glycol, ethylhexylglycerin, and p-anisic acid (Sample No. 3-2) or the combination of 1,3-propanediol, methylpropanediol, and p-anisic acid (Sample No. 5-2) did not cause mold mycelia or moisture condensation in the powder formulation in a high-humidity environment, and thus it was confirmed to have excellent safety and excellent stability.

Claims (10)

An antimicrobial composition applicable to a powder formulation, comprising caprylyl glycol, ethylhexylglycerin, and p-anisic acid. An antibacterial composition applicable to a powder formulation, wherein the weight ratio of caprylyl glycol, ethylhexylglycerin, and p-anisic acid in claim 1 is 1 to 32:1 to 16:1 to 32. In claim 1, with respect to the total weight of the composition, The above caprylyl glycol is contained in an amount of 0.004 to 5 wt%, The above ethylhexylglycerin is contained in an amount of 0.004 to 5 wt%, and An antibacterial composition applicable to a powder formulation, wherein the above p-anisic acid is contained in an amount of 0.02 to 0.5 wt%. An antimicrobial composition applicable to a powder formulation, comprising 1,3-propanediol, methylpropanediol, and p-anisic acid. An antibacterial composition applicable to a powder formulation, wherein the weight ratio of 1,3-propanediol, methylpropanediol, and p-anisic acid in claim 4 is 1 to 512:1 to 512:1. In claim 4, with respect to the total weight of the composition, The above 1,3-propanediol is contained in an amount of 0.25 to 32 wt%, The above methylpropanediol is contained in an amount of 0.25 to 32 wt%, and An antibacterial composition applicable to a powder formulation, wherein the above p-anisic acid is contained in an amount of 0.02 to 0.5 wt%. An antimicrobial composition applicable to a powder formulation, which exhibits antimicrobial activity against at least one selected from bacteria, yeast, and mold according to claim 1 or 4. In claim 7, The above bacteria include at least one selected from Escherichia coli , Pseudomonas aeruginosa , and Staphylococcus aureus . The above yeast includes Candida albicans, An antimicrobial composition applicable to a powder formulation, wherein the mold comprises Aspergillus brasiliensis . A cosmetic composition comprising an antimicrobial composition applicable to the powder formulation of claim 1 or 4. A composition for external use in the skin comprising an antibacterial composition applicable to the powder formulation of claim 1 or 4.

Images